Entera Bio LTD Form 4 insider transactions

Steven D Rubin, a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Yonatan Malca, a Director of Entera Bio Ltd., received 22,815 shares of common stock on August 7, 2026.

Haya Taitel, a Director of Entera Bio Ltd., received 20,790 shares of common stock on August 7, 2026.

Sean Ellis, a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Dana Yaacov-Garbeli, Chief Financial Officer of Entera Bio Ltd., received 140,000 shares of common stock on August 7, 2026.

Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd., received 200,000 shares of common stock on August 7, 2026.

Gregory Burshtein, Chief of R&D of Entera Bio Ltd., received 180,000 shares of common stock on August 7, 2026.

Miranda Jayne Toledano, Chief Executive Officer and a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Geno J Germano, a Director of Entera Bio Ltd., reported multiple transactions in common stock on August 7, 2026.

Miranda Jayne Toledano, Chief Executive Officer and a Director of Entera Bio Ltd., reported multiple transactions in common stock on July 14, 2026.

Entera Bio Ltd. Chief Operating Officer Hillel Galitzer was granted 72,993 restricted stock units in lieu of a cash bonus.

Entera Bio CFO Dana Yaacov-Garbeli was granted 58,394 restricted stock units in lieu of a cash bonus.

Gregory Burshtein, Chief of R&D at Entera Bio, received 87,591 restricted stock units in lieu of a cash bonus.

Entera Bio Ltd. Director and 10% owner Steven D. Rubin acquired 5,000 ordinary shares at $1.49 per share, increasing his direct beneficial ownership to 15,000 shares.

Entera Bio Ltd. Director Haya Taitel acquired 7,500 ordinary shares for approximately $11,100, increasing her beneficial ownership.

Entera Bio Ltd. Director Geno J Germano acquired 20,000 ordinary shares at $1.49 per share, effective February 10, 2026, under a 10b5-1 plan.

Entera Bio Ltd. Director Steven D. Rubin plans to acquire 10,000 ordinary shares at $1.20 per share on February 9, 2026.

Entera Bio Ltd. Director Sean Ellis acquired 18,000 ordinary shares at a weighted average price of $1.24, increasing his direct beneficial ownership to 178,098 shares.

Entera Bio Ltd. Director Gerald M. Ostrov received 28,721 ordinary shares and 33,505 stock options as compensation for services.

Entera Bio Ltd. Director Sean Ellis was awarded 25,371 ordinary shares in lieu of cash fees and granted 33,505 stock options as part of annual director compensation.

Entera Bio Ltd. Director Yonatan Malca was granted ordinary shares and stock options as compensation for services.

Entera Bio Ltd. director Gerald M. Lieberman received 38,294 ordinary shares in lieu of cash fees and an annual grant of 33,505 stock options.

Entera Bio Ltd. Director Haya Taitel acquired 26,329 ordinary shares and 33,505 stock options as compensation for director services and annual grant.

Entera Bio Ltd.'s CEO, Miranda Jayne Toledano, acquired 11,000 ordinary shares at a weighted average price of $1.8102, increasing her direct beneficial ownership to 426,575 shares.

Entera Bio Ltd.'s Chief Executive Officer, Miranda Jayne Toledano, received significant equity awards, including restricted stock units and stock options, following shareholder approval on July 16, 2025.

Entera Bio Ltd. has granted 26,316 restricted stock units and 200,000 stock options to its Chief of R&D, Gregory Burshtein, following shareholder approval.

Entera Bio Ltd.'s Chief Financial Officer, Dana Yaacov-Garbeli, received a significant grant of restricted stock units and stock options, approved by shareholders on July 16, 2025, in lieu of her 2024 cash bonus.

Hillel Galitzer, Chief Operating Officer of Entera Bio Ltd., reports the acquisition of restricted stock units and stock options.

Director Gerald M. Lieberman exercised warrants to acquire 23,952 ordinary shares of Entera Bio Ltd. at a price of $1 per share on April 1, 2025.

A director of Entera Bio Ltd. received shares and stock options as compensation for services and as part of an annual grant.